U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

You searched for: Journal name Vaccine Remove constraint Journal name: Vaccine Subject term antigens Remove constraint Subject term: antigens
Start Over

Search

1,736  Search Results

« Previous | 1 - 50 of 1,736 |
Number of results to display per page

Search Results

1. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice

Author:
Xian Yu; Yan Wang; Yifan Xia; Lijuan Zhang; Qin Yang; Jun Lei
Source:
Vaccine 2016 v.34 no.37 pp. 4399-4405
ISSN:
0264-410X
Subject:
immunoglobulin G; antibiotic resistance; T-lymphocytes; Human alphaherpesvirus 1; antigens; DNA; cell-mediated immunity; interferon-gamma; vaccination; mice; viruses; genes; immune response; recombinant vaccines; Pseudomonas aeruginosa; herpes simplex; cell proliferation; protective effect
Abstract:
... Pseudomonas aeruginosa antimicrobial resistance is a major therapeutic challenge. DNA vaccination is an attractive approach for antigen-specific immunotherapy against P. aeruginosa. We explored the feasibility of employing Herpes simplex virus type 1 tegument protein, VP22, as a molecular tool to enhance the immunogenicity of an OprF DNA vaccine against P. aeruginosa. Recombinant DNA vaccines, pVA ...
DOI:
10.1016/j.vaccine.2016.07.017

2. A DNA vaccine encoding the E protein of West Nile Virus is protective and can be boosted by recombinant domain DIII

Author:
Anne Schneeweiss; Stefan Chabierski; Mathias Salomo; Nicolas Delaroque; Samiya Al-Robaiy; Thomas Grunwald; Kurt Bürki; Uwe G. Liebert; Sebastian Ulbert
Source:
Vaccine 2011 v.29 no.37 pp. 6352-6357
ISSN:
0264-410X
Subject:
T-lymphocytes; West Nile virus; antigens; birds; cell-mediated immunity; humans; immune response; mice; neutralization; neutralizing antibodies; plasmids; proteins; recombinant vaccines; vaccination; virus-like particles; viruses
Abstract:
... West Nile Virus (WNV) is an emerging pathogenic flavivirus with increasing distribution worldwide. Birds are the natural host of the virus, but also mammals, including humans, can be infected. In some cases, a WNV infection can be associated with severe neurological symptoms. All currently available WNV vaccines are in the veterinary sector, and there is a need to develop safe and effective immuni ...
DOI:
10.1016/j.vaccine.2011.04.116

3. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR⁻/⁻ mice upon lethal virus challenge

Author:
Hani Boshra; Gema Lorenzo; Fernando Rodriguez; Alejandro Brun
Source:
Vaccine 2011 v.29 no.27 pp. 4469-4475
ISSN:
0264-410X
Subject:
antigens; T-lymphocytes; antibodies; plasmids; Rift Valley fever phlebovirus; mice; vaccination; animal models; genes; immune response; recombinant vaccines; vaccine development; viruses; glycoproteins
Abstract:
... Current vaccine candidates against Rift Valley fever virus (RVFV) incorporate the viral structural glycoproteins as antigens, since triggering antibody responses against them usually correlates with protection. Here, we have focused solely on the nucleoprotein of RVFV as a potential target for vaccine development. Previous studies in mouse models have already demonstrated that RVFV nucleoprotein c ...
DOI:
10.1016/j.vaccine.2011.04.043

4. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer

Author:
Fei Geng; Jie Guo; Qian-Qian Guo; Yu Xie; Ling Dong; Yi Zhou; Chen-Lu Liu; Bin Yu; Hui Wu; Jia-Xin Wu; Hai-Hong Zhang; Wei Kong; Xiang-Hui Yu
Source:
Vaccine 2019 v.37 no.31 pp. 4382-4391
ISSN:
0264-410X
Subject:
CD8-positive T-lymphocytes; animal models; antigens; antineoplastic activity; breast neoplasms; chemokine CCL2; chemokine CXCL12; clinical trials; codons; fibroblasts; humans; immune response; immunogenicity; metastasis; mice; recombinant vaccines; secretion; signal peptide; suppressor cells; t-plasminogen activator
Abstract:
... Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time ...
DOI:
10.1016/j.vaccine.2019.06.012

5. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization

Author:
David I. Bernstein; Marcela F. Pasetti; Rebecca Brady; Amanda D. Buskirk; Rezwanul Wahid; Michelle Dickey; Mitchell Cohen; Holly Baughman; Jill El-Khorazaty; Nicole Maier; Marcelo B. Sztein; Shahida Baqar; A. Louis Bourgeois
Source:
Vaccine 2019 v.37 no.4 pp. 602-611
ISSN:
0264-410X
Subject:
T-lymphocytes; adults; antigens; blood serum; cytokines; diarrhea; dose response; enterotoxigenic Escherichia coli; immunogenicity; immunoglobulin A; immunoglobulin G; mutants; neutralizing antibodies; oral administration; oral vaccination; public health; saliva; toxigenic strains; vaccines; vomiting
Abstract:
... The public health burden of Enterotoxigenic Escherichia coli (ETEC) is high but no vaccine is specifically approved to prevent ETEC infections.We performed a Phase 1, dose escalation study (1–50 µg) evaluating the sublingual (SL) delivery of the double mutant heat-labile toxin LTR192G/L211A (dmLT) in 80 healthy adult volunteers. The primary objective was safety and the secondary was the immunogeni ...
DOI:
10.1016/j.vaccine.2018.12.011
PubMed:
30563789
PubMed Central:
PMC6331259

6. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA

Author:
Sharon E. Frey; Kathleen R. Lottenbach; Heather Hill; Tamara P. Blevins; Yinyi Yu; Ying Zhang; Karen E. Brenneman; Sandra M. Kelly-Aehle; Caitlin McDonald; Angela Jansen; Roy Curtiss
Source:
Vaccine 2013 v.31 no.42 pp. 4874-4880
ISSN:
0264-410X
Subject:
immunoglobulin G; lipopolysaccharides; antigens; animals; vaccines; enzyme-linked immunosorbent assay; immunoglobulin A; outer membrane proteins; Streptococcus pneumoniae; immune response; vaccination; surface proteins; blood; Salmonella Typhi; adults
Abstract:
... Live, attenuated, orally-administered Salmonella strains are excellent vectors for vaccine antigens and are attractive as vaccines based on previous use of S. Typhimurium in animals. A Phase I dose escalation trial was conducted to evaluate the safety and immunogenicity of three newly constructed recombinant attenuated Salmonella enterica serovar Typhi vaccine (RASV) vectors synthesizing Streptoco ...
DOI:
10.1016/j.vaccine.2013.07.049

7. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine

Author:
Aristine Cheng; Chang-Phone Fung; Chia-Chyi Liu; Yi-Tsung Lin; Hsih-Yeh Tsai; Shan-Chwen Chang; Ai-Hsiang Chou; Jui-Yuan Chang; Ren-Huei Jiang; Yi-Chin Hsieh; Ih-Jen Su; Pele Choi-Sing Chong; Szu-Min Hsieh
Source:
Vaccine 2013 v.31 no.20 pp. 2471-2476
ISSN:
0264-410X
Subject:
adults; antigens; cell culture; death; encephalitis; immune response; injection site; neutralization; pain; paralysis; seroconversion; vaccination; vaccines; volunteers
Abstract:
... Large-scale outbreaks of enterovirus 71 (EV71) infections have occurred in Asia-Pacific regions. Severe complications include encephalitis and poliomyelitis-like paralysis, cardiopulmonary collapse, and death, necessitating an effective vaccine against EV71.In this randomized Phase I study, we evaluated the safety and immunogenicity of an inactivated alum-adjuvanted EV71 whole-virus vaccine produc ...
DOI:
10.1016/j.vaccine.2013.03.015

8. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States

Author:
Lee-Jah Chang; James Hedrick; Shane Christensen; Judy Pan; Emilia Jordanov; Mandeep S. Dhingra
Source:
Vaccine 2020 v.38 no.19 pp. 3560-3569
ISSN:
0264-410X
Subject:
Papillomaviridae; adolescents; antibodies; antibody formation; antigens; blood serum; complement; diphtheria; humans; immunogenicity; serotypes; tetanus; vaccination; vaccines; United States
Abstract:
... MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for use in individuals ≥6 weeks of age. We evaluated the safety and immunogenicity of MenACYW-TT when compared to a licensed quadrivalent conjugate meningococcal vaccine (Menveo®; MCV4-CRM; GlaxoSmithKline, Italy), and when co-administered with tetanus, diphtheria, acellular pertussis (Tdap) and human papilloma ...
DOI:
10.1016/j.vaccine.2020.03.017

9. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months

Author:
Sven-Arne Silfverdal; Giancarlo Icardi; Timo Vesikari; Sheryl A. Flores; Marco F. Pagnoni; Jin Xu; G. Frank Liu; Jon E. Stek; Florence Boisnard; Stéphane Thomas; Eddy Ziani; Andrew W. Lee
Source:
Vaccine 2016 v.34 no.33 pp. 3810-3816
ISSN:
0264-410X
Subject:
antigens; clinical trials; fever; immune response; infants; infectious diseases; somnolence; vaccination; vaccines; Finland; Italy; Sweden
Abstract:
... Combination vaccines simplify vaccination visits and improve coverage and timeliness. DTaP5-HB-IPV-Hib is a new investigational, fully-liquid, combination vaccine designed to protect against 6 infectious diseases, including 5 pertussis antigens and OMPC instead of PT as conjugated protein for Hib component.In this multicenter, double-blind, comparator-controlled, Phase III study (NCT01480258) cond ...
DOI:
10.1016/j.vaccine.2016.05.054

10. A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Intranasally Administered Trivalent Inactivated Influenza Vaccine with Adjuvant LTh(αK): A Phase I Study

Author:
Sung-Ching Pan; Szu-Min Hsieh; Chih-Feng Lin; Yu-Shen Hsu; Mingi Chang; Shan-Chwen Chang
Source:
Vaccine 2019 pp. -
ISSN:
0264-410X
Subject:
Escherichia coli; Influenza A virus; adjuvants; antibodies; antigens; arrhythmia; clinical trials; enterotoxins; fever; headache; hemagglutination; immunogenicity; immunoglobulin A; influenza; influenza vaccines; live vaccines; mucosal immunity; nose; viruses
Abstract:
... A nasal influenza vaccine has been available only in a live attenuated form, which limits the range of recipients to immune-competent individuals. The present study evaluated a newly developed intranasal inactivated influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT) derived from E. coli (LTh(αK)).The study was a randomized, double-blind, controlled phase I trial to evaluate the ...
DOI:
10.1016/j.vaccine.2019.02.006

11. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

Author:
Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M. de la Maza
Source:
Vaccine 2011 v.29 no.38 pp. 6641-6649
ISSN:
0264-410X
Subject:
Chlamydia trachomatis; Neisseria gonorrhoeae; T-lymphocytes; Toll-like receptors; adjuvants; agonists; antigens; body weight changes; cell proliferation; cell-mediated immunity; flagellin; humoral immunity; immune response; immunization; interferon-gamma; intracellular signaling peptides and proteins; lipid A; lungs; mice; outer membrane proteins; pathogens; pneumonia; porins; vaccines
Abstract:
... Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen in the World and there is an urgent need for a vaccine to prevent these infections. To determine what type of adjuvant can better enhance the immunogenicity of a Chlamydia vaccine, we formulated the recombinant major outer membrane protein (Ct-rMOMP) with several ligands for Toll-like receptors (TLR) and the nucl ...
DOI:
10.1016/j.vaccine.2011.06.105
PubMed:
21742006
PubMed Central:
PMC3156873

12. A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy

Author:
Jiangxue Wei; Zhengjun Li; Yanli Yang; Xiaowei Ma; Wenqi An; Guanghui Ma; Zhiguo Su; Songping Zhang
Source:
Vaccine 2020 v.38 no.38 pp. 5987-5996
ISSN:
0264-410X
Subject:
Hepatitis B virus; Influenza A virus; adjuvants; antigens; biomimetics; body weight changes; encapsulation; immunization; influenza; influenza vaccines; lymph nodes; memory; nucleoproteins; peptides; temperature; vaccine development
Abstract:
... Here we present a biomimetic strategy towards an influenza vaccine design based on hepatitis B virus core virus-like particles (HBc VLP). To this end, a temperature-shift based encapsulation process based on analysis of the unique thermal-associated structural flexibility of HBc VLP nanocages was proposed and proved efficient for encapsulation of antigen inside the VLP. By displaying a matrix prot ...
DOI:
10.1016/j.vaccine.2020.07.015

13. A bivalent Vibrio harveyi DNA vaccine induces strong protection in Japanese flounder (Paralichthys olivaceus)

Author:
Yong-hua Hu; Li Sun
Source:
Vaccine 2011 v.29 no.26 pp. 4328-4333
ISSN:
0264-410X
Subject:
Paralichthys olivaceus; Vibrio harveyi; Vibrio parahaemolyticus; antibodies; antigens; aquaculture; blood serum; flounder; genes; kidneys; messenger RNA; models; muscle tissues; muscles; pathogens; plasmids; proteins; recombinant vaccines; spleen; survival rate; vaccination; vibriosis
Abstract:
... Vibrio harveyi is a severe aquaculture pathogen that can infect a large number of fish species. In previous studies, we have identified two protective immunogens, DegQ and Vhp1, from pathogenic V. harveyi strains. In this study, we examined the potentials of DegQ and Vhp1 as monovalent and bivalent DNA vaccines in a Japanese flounder (Paralichthys olivaceus) model. For this purpose, the DNA vaccin ...
DOI:
10.1016/j.vaccine.2011.04.021

14. A bivalent vaccine derived from attenuated Salmonella expressing O-antigen polysaccharide provides protection against avian pathogenic Escherichia coli O1 and O2 infection

Author:
Yue Han; Qing Liu; Stephan Willias; Kang Liang; Pei Li; Anchun Cheng; Qingke Kong
Source:
Vaccine 2018 v.36 no.8 pp. 1038-1046
ISSN:
0264-410X
Subject:
Escherichia coli; O-antigens; Salmonella Typhimurium; Western blotting; antibacterial properties; antibodies; antigens; biosynthesis; blood serum; chickens; complement; financial economics; immune response; immunization; immunoglobulin G; mixing; models; multigene family; oxygen; plasmids; poultry industry; serotypes; vaccines; virulence
Abstract:
... Avian pathogenic Escherichia coli (APEC), a leading cause of avian airsacculitis and colibacillosis, is responsible for significant economic loss in the poultry industry. APEC serogroups O1, O2, and O78 are predominantly associated with disease. Lipopolysaccharide (LPS) O-antigen has been shown to be a potent antigen for inducing specific protective immune responses. Therefore, we sought to develo ...
DOI:
10.1016/j.vaccine.2018.01.036

15. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi

Author:
Ying-Jie Lu; Fan Zhang; Sabina Sayeed; Claudette M. Thompson; Shousun Szu; Porter W. Anderson; Richard Malley
Source:
Vaccine 2012 v.30 no.23 pp. 3405-3412
ISSN:
0264-410X
Subject:
antigens; cell walls; serotypes; vaccines; typhoid fever; developing countries; mice; children; Streptococcus pneumoniae; clinical trials; Salmonella Typhi
Abstract:
... Pneumococcal and Salmonella typhi infections are two major diseases for children in developing countries. For typhoid fever, licensed Vi polysaccharide vaccines are ineffective in children <2-year old. While investigational Vi conjugate vaccines have been shown effective in clinical trials, they are currently only available to restricted areas. Pneumococcal capsular polysaccharide conjugate vaccin ...
DOI:
10.1016/j.vaccine.2012.03.039
PubMed:
22465750
PubMed Central:
PMC3334478

16. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice

Author:
Xiaoli Wang; Zhiqiang Ku; Wenlong Dai; Tan Chen; Xiaohua Ye; Chao Zhang; Yingyi Zhang; Qingwei Liu; Xia Jin; Zhong Huang
Source:
Vaccine 2015 v.33 no.43 pp. 5779-5785
ISSN:
0264-410X
Subject:
Enterovirus A; Norovirus; antibodies; antigens; children; gastroenteritis; hand, foot and mouth disease; immune response; mice; morbidity; mortality; mucins; neutralization; virus-like particle vaccines; virus-like particles
Abstract:
... Noroviruses are the main cause of severe viral gastroenteritis, which results in estimated 200,000 deaths each year, primarily in children in the developing world. Genogroup II.4 (GII.4) strains are responsible for the majority of norovirus outbreaks. Enterovirus 71 (EV71), the leading causative agent of hand, foot and mouth disease, has recently been prevalent in Asia-Pacific regions, resulting i ...
DOI:
10.1016/j.vaccine.2015.09.043

17. A brief review on the immunological scenario and recent developmental status of vaccines against enteric fever

Author:
Debaki Ranjan Howlader; Hemanta Koley; Suhrid Maiti; Ushasi Bhaumik; Priyadarshini Mukherjee; Shanta Dutta
Source:
Vaccine 2017 v.35 no.47 pp. 6359-6366
ISSN:
0264-410X
Subject:
Salmonella Paratyphi A; Salmonella Typhi; antigens; developed countries; epidemiology; fever; multiple drug resistance; typhoid fever; vaccines; Asia
Abstract:
... Enteric fever has been one of the leading causes of severe illness and deaths worldwide. S. Typhi and S. Paratyphi A, B and C are important enteric fever-causing organisms globally. This infection causes about 21 million cases among which 222,000 typhoid related deaths occurred in 2015. These estimates do not reflect the ultimate and real status of the disease due to the lack of unified diagnostic ...
DOI:
10.1016/j.vaccine.2017.09.066

18. A broad protection provided by matrix protein 2 (M2) of avian influenza virus

Author:
Qingwen Meng; Guangliang Liu; Yonggang Liu; Xiaoxia Deng; Wei Wang; Kehui Xu; Xiangdong Zheng; Dongwei Zhang; Hai Pang; Hongyan Chen
Source:
Vaccine 2015 v.33 no.31 pp. 3758-3765
ISSN:
0264-410X
Subject:
Escherichia coli; Influenza A virus; antibodies; antigens; immunization; ion channels; mice; molecular weight; pandemic; progeny; vaccine development; vaccines; virus replication
Abstract:
... To prevent a future influenza A virus subtype pandemic outbreak, developing a broad-spectrum vaccine would be highly beneficial. The ion channel protein M2 is highly conserved in a diverse number of influenza A virus subtypes. This distinguishing characteristic makes M2 an attractive vaccine target for a broadly protective vaccine. We expressed a full-length M2 protein which was C-terminally fused ...
DOI:
10.1016/j.vaccine.2015.05.045

19. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)

Author:
Oliver Koeberling; Emma Ispasanie; Julia Hauser; Omar Rossi; Gerd Pluschke; Dominique A. Caugant; Allan Saul; Calman A. MacLennan
Source:
Vaccine 2014 v.32 no.23 pp. 2688-2695
ISSN:
0264-410X
Subject:
Neisseria meningitidis; Toll-like receptor 4; antibodies; antigens; burden of disease; disease outbreaks; gene overexpression; genes; humans; interleukin-6; kidney cells; loci; meningitis; mice; mononuclear leukocytes; mutants; serotypes; vaccines; Sub-Saharan Africa
Abstract:
... Neisseria meningitidis causes epidemics of meningitis in sub-Saharan Africa. These have mainly been caused by capsular group A strains, but W and X strains are increasingly contributing to the burden of disease. Therefore, an affordable vaccine that provides broad protection against meningococcal disease in sub-Saharan Africa is required.We prepared Generalized Modules for Membrane Antigens (GMMA) ...
DOI:
10.1016/j.vaccine.2014.03.068

20. A candidate dual vaccine against influenza and noroviruses

Author:
Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Source:
Vaccine 2011 v.29 no.44 pp. 7670-7677
ISSN:
0264-410X
Subject:
Orthomyxoviridae; antigens; chimerism; human influenza; immune response; immunization; mice; peptides; receptors; survival rate; vaccines
Abstract:
... The extracellular domain of the matrix protein 2 (M2e) of influenza viruses is highly conserved among all influenza A subtypes, making it a suitable target for a universal influenza vaccine. In this study, we demonstrated an enhanced immune response and protection of a chimeric M2e vaccine against influenza A viruses using our newly developed vaccine platform, the norovirus P particle, to present ...
DOI:
10.1016/j.vaccine.2011.07.139
PubMed:
21839795
PubMed Central:
PMC3190067

21. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs

Author:
Annebel R. De Vleeschauwer; Xiaocui Zhou; David J. Lefebvre; Annabelle Garnier; Fleur Watier; Charly Pignon; Sandrine A. Lacour; Stephan Zientara; Labib Bakkali-Kassimi; Kris De Clercq; Bernard Klonjkowski
Source:
Vaccine 2018 v.36 no.16 pp. 2193-2198
ISSN:
0264-410X
Subject:
vector vaccines; antigens; humoral immunity; capsid; antibodies; hosts; models; disease control; vaccination; Canine mastadenovirus A; mice; structural proteins; foot-and-mouth disease; immune response; Foot-and-mouth disease virus; guinea pigs; emulsions
Abstract:
... Vaccination is a key element in the control of foot-and-mouth disease (FMD). The majority of the antigenic sites that induce protective immune responses are localized on the FMD virus (FMDV) capsid that is formed by four virus-encoded structural proteins, VP1 to VP4. In the present study, recombinant canine adenovirus type 2 (CAV2)-based FMD vaccines, Cav-P1/3C R° and Cav-VP1 R°, respectively expr ...
DOI:
10.1016/j.vaccine.2018.02.074

22. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03

Author:
Takeshi Naruse; Tadashi Fukuda; Tetsuro Tanabe; Munetaka Ichikawa; Yoshiaki Oda; Shinji Tochihara; Kazuhiko Kimachi; Yoichiro Kino; Kohji Ueda
Source:
Vaccine 2015 v.33 no.45 pp. 6078-6084
ISSN:
0264-410X
Subject:
adults; antigens; clinical trials; guidelines; hemagglutination; influenza; males; neutralizing antibodies; pandemic; vaccines; viruses; volunteers
Abstract:
... We conducted a phase I clinical trial of a cell culture-derived AS03-adjuvanted influenza vaccine containing HA antigen (A/Indonesia/05/2005(H5N1)/PR8-IBCDC-RG2) derived from EB66 cells (KD-295).Healthy male adult volunteers (20–40 years old, N=60) enrolled in the study were divided into 3 groups, the MA group (3.8μg of HA+AS03), HA group (7.5μg of HA+AS03), and 1/2 MA group (half the volume of th ...
DOI:
10.1016/j.vaccine.2015.09.022

23. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

Author:
Jaya Chakravarty; Subodh Kumar; Sonali Trivedi; Vijay K. Rai; Anup Singh; Jill A. Ashman; Elsa M. Laughlin; Rhea N. Coler; Stuart J. Kahn; Anna Marie Beckmann; Karen D. Cowgill; Steven G. Reed; Shyam Sundar; Franco M. Piazza
Source:
Vaccine 2011 v.29 no.19 pp. 3531-3537
ISSN:
0264-410X
Subject:
Leishmania donovani; T-lymphocytes; adults; agglutination tests; antigens; clinical trials; cytokines; immune response; interferon-gamma; vaccines; visceral leishmaniasis; volunteers
Abstract:
... Healthy Indian adult volunteers, with or without a history of leishmaniasis, were evaluated for evidence of previous infection with Leishmania donovani based on the direct agglutination test (DAT). Three cohorts of 6 DAT-negative and 6 DAT-positive subjects were enrolled in an open-label, dose-escalating, uncontrolled clinical trial and received three injections of the LEISH-F1+MPL-SE vaccine (con ...
DOI:
10.1016/j.vaccine.2011.02.096

24. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions

Author:
Tanja Opriessnig; Chao-Ting Xiao; Patrick G. Halbur; Priscilla F. Gerber; Shannon R. Matzinger; Xiang-Jin Meng
Source:
Vaccine 2017 v.35 no.2 pp. 248-254
ISSN:
0264-410X
Subject:
Porcine circovirus; Porcine circovirus-2; antigens; blood serum; feces; genotype; herds; lymph nodes; necropsy; nose; seroprevalence; swine; vaccination; vaccines; viremia
Abstract:
... Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against exper ...
DOI:
10.1016/j.vaccine.2016.11.085
PubMed:
27919634
PubMed Central:
PMC5221148

25. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain

Author:
Tanja Opriessnig; Priscilla F. Gerber; Chao-Ting Xiao; Mark Mogler; Patrick G. Halbur
Source:
Vaccine 2014 v.32 no.2 pp. 230-237
ISSN:
0264-410X
Subject:
DNA; Porcine circovirus; Porcine reproductive and respiratory syndrome virus; antigens; models; swine; vaccination; vaccines; viremia; United States
Abstract:
... During 2012 and 2013, an apparent increase in porcine circovirus associated disease occurred in the USA. A variant PCV2b strain designated mPCV2b was recovered from many of these cases. This raised concerns of a decrease in efficacy of commercially available PCV2 vaccines. The objective of this study was to compare the ability of a commercial PCV2a-based vaccine and an experimental mPCV2b-based va ...
DOI:
10.1016/j.vaccine.2013.11.010

26. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings—A randomised blind study

Author:
Sarah Gildea; Sean Arkins; Cathal Walsh; Ann Cullinane
Source:
Vaccine 2011 v.29 no.49 pp. 9214-9223
ISSN:
0264-410X
Subject:
Thoroughbred; antibodies; antigens; at-risk population; equine influenza; farms; hemagglutinins; hemolysis; horses; immune response; inactivated vaccines; issues and policy; marketing; recombinant vaccines; vaccination; viruses; weanlings; Ireland
Abstract:
... Many racing authorities, sales companies and equestrian bodies have mandatory vaccination policies for equine influenza (EI). The consequences of lack of vaccine efficacy include clinical disease, disruption to training programmes, the cancellation of equestrian events and the introduction of virus to susceptible populations. The correlation between antibody against the virus haemagglutinin and pr ...
DOI:
10.1016/j.vaccine.2011.09.101
CHORUS:
10.1016/j.vaccine.2011.09.101

27. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen

Author:
William M. Gwinn; Brandi T. Johnson; Shaun M. Kirwan; Ashley E. Sobel; Soman N. Abraham; Michael D. Gunn; Herman F. Staats
Source:
Vaccine 2013 v.31 no.11 pp. 1480-1489
ISSN:
0264-410X
Subject:
T-lymphocytes; anthrax; antibodies; antigens; biomarkers; blood serum; humans; humoral immunity; immune response; immunization; immunoglobulin A; immunoglobulin E; immunoglobulin G; innate immunity; interleukin-1alpha; mice; nose; toxicity; vaccine adjuvants; vaccines
Abstract:
... Development of nasal immunization for human use is hindered by the lack of acceptable adjuvants. Although CT is an effective adjuvant, its toxicity will likely prevent its use in nasal vaccines. This study compared non-toxin adjuvants to CT for their ability to induce protective antibody responses with nasal immunization. C3H/HeN and C57BL/6 mice were immunized with rPA formulated with the followi ...
DOI:
10.1016/j.vaccine.2013.01.012
PubMed:
23352329
PubMed Central:
PMC3622208

28. A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains

Author:
Ted M. Ross; Joshua DiNapoli; Maryann Giel-Moloney; Chalise E. Bloom; Kateri Bertran; Charles Balzli; Tod Strugnell; Mariana Sá e Silva; Teshome Mebatsion; Michel Bublot; David E. Swayne; Harry Kleanthous
Source:
Vaccine 2019 v.37 no.17 pp. 2369-2376
ISSN:
0264-410X
Subject:
Influenza A virus; antibodies; antigens; chickens; ducks; genes; hemagglutination; hemagglutinins; humans; influenza vaccines; pandemic; phylogeny; swans; virus-like particle vaccines; viruses
Abstract:
... Since the first identification of the H5N1 Goose/Guangdong lineage in 1996, this highly pathogenic avian influenza virus has spread worldwide, becoming endemic in domestic poultry. Sporadic transmission to humans has raised concerns of a potential pandemic and underscores the need for a broad cross-protective influenza vaccine. Here, we tested our previously described methodology, termed Computati ...
Handle:
10113/6338104
DOI:
10.1016/j.vaccine.2019.03.018
CHORUS:
10.1016/j.vaccine.2019.03.018

29. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets

Author:
Brendan M. Giles; Ted M. Ross
Source:
Vaccine 2011 v.29 no.16 pp. 3043-3054
ISSN:
0264-410X
Subject:
Influenza A virus; amino acid sequences; antibodies; antigens; avian influenza; ferrets; human diseases; human population; mice; mortality; pandemic; vaccine development; virus-like particle vaccines; viruses
Abstract:
... Pandemic outbreaks of influenza are caused by the emergence of a pathogenic and transmissible virus to which the human population is immunologically naïve. Recent outbreaks of highly pathogenic avian influenza (HPAI) of the H5N1 subtype are of particular concern because of the high mortality rate (60% case fatality rate) and novel subtype. In order to develop a vaccine that elicits broadly reactiv ...
DOI:
10.1016/j.vaccine.2011.01.100
PubMed:
21320540
PubMed Central:
PMC3090662

30. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells

Author:
Michael A. McVoy; Ronzo Lee; Frances M. Saccoccio; Jukka Hartikka; Larry R. Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P. Adler
Source:
Vaccine 2015 v.33 no.51 pp. 7328-7336
ISSN:
0264-410X
Subject:
Cytomegalovirus; T-lymphocytes; adjuvants; antigens; cytotoxicity; epithelial cells; epithelium; fibroblasts; glycoproteins; humans; mice; neutralization; neutralizing antibodies; phosphoproteins; rabbits; recombinant vaccines
Abstract:
... A vaccine to prevent congenital cytomegalovirus (CMV) infections is a national priority. Investigational vaccines have targeted the viral glycoprotein B (gB) as an inducer of neutralizing antibodies and phosphoprotein 65 (pp65) as an inducer of cytotoxic T cells. Antibodies to gB neutralize CMV entry into all cell types but their potency is low compared to antibodies that block epithelial cell ent ...
DOI:
10.1016/j.vaccine.2015.10.078
PubMed:
26597035
PubMed Central:
PMC4684450

31. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants

Author:
M. Tameris; D.A. Hokey; V. Nduba; J. Sacarlal; F. Laher; G. Kiringa; K. Gondo; E.M. Lazarus; G.E. Gray; S. Nachman; H. Mahomed; K. Downing; B. Abel; T.J. Scriba; J.B. McClain; M.G. Pau; J. Hendriks; V. Dheenadhayalan; S. Ishmukhamedov; A.K.K. Luabeya; H. Geldenhuys; B. Shepherd; G. Blatner; V. Cardenas; R. Walker; W.A. Hanekom; J. Sadoff; M. Douoguih; L. Barker; M. Hatherill
Source:
Vaccine 2015 v.33 no.25 pp. 2944-2954
ISSN:
0264-410X
Subject:
CD8-positive T-lymphocytes; Mycobacterium tuberculosis; adults; antibodies; antigens; clinical trials; immune response; infants; placebos; tuberculosis; vaccines; Sub-Saharan Africa
Abstract:
... Several novel tuberculosis vaccines are currently in clinical trials, including AERAS-402, an adenovector encoding a fusion protein of Mycobacterium tuberculosis antigens 85A, 85B, and TB10.4. A multicentred trial of AERAS-402 safety and immunogenicity in healthy infants was conducted in three countries in sub-Saharan Africa, using an adaptive design.In a double-blind, randomised, placebo-controll ...
DOI:
10.1016/j.vaccine.2015.03.070
PubMed:
25936724
PubMed Central:
PMC6698638

32. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study

Author:
Sung-Ching Pan; Wei-Ting Hsu; Wen-Sen Lee; Ning-Chi Wang; Tzeng-Ji Chen; Ming-Che Liu; Hui-Chen Pai; Yu-Shen Hsu; Mingi Chang; Szu-Min Hsieh
Source:
Vaccine 2020 v.38 no.5 pp. 1048-1056
ISSN:
0264-410X
Subject:
Escherichia coli; adjuvants; antibodies; antibody formation; antigens; blood serum; diarrhea; enterotoxins; hemagglutinins; immunogenicity; immunoglobulin A; inactivated vaccines; influenza; influenza vaccines; live vaccines; nose; randomized clinical trials
Abstract:
... Intranasal influenza vaccines may provide protective efficacy by inducing both systemic antibodies and local secretory IgA. Live attenuated intranasal vaccines are not feasible for high-risk groups. A previously constructed inactivated vaccine with adjuvant revealed an association with neurological events in some studies. In this phase II trial, we aimed to evaluate the safety and immunogenicity o ...
DOI:
10.1016/j.vaccine.2019.11.047

33. A dual kisspeptin-GnRH immunogen for reproductive immunosterilization

Author:
Jesus A. Junco; Franklin Fuentes; Robert P. Millar
Source:
Vaccine 2021 v.39 no.43 pp. 6437-6448
ISSN:
0264-410X
Subject:
CD4-positive T-lymphocytes; adults; amino acid sequences; antigens; estradiol; females; hepatitis B; immunization; immunocontraception; kisspeptin; males; puberty; sheep; testosterone; vaccines
Abstract:
... GnRH immunogens have been extensively employed in immunocontraception of animals. While they are effective, they are not 100% efficacious and of limited duration. GnRH secretion is dependent on upstream stimulation by kisspeptin. We therefore hypothesised that a dual immunogen combining GnRH and kisspeptin may be more efficacious through targeting two levels of the axis. We have previously shown G ...
DOI:
10.1016/j.vaccine.2021.07.080

34. A ferritin nanoparticle vaccine for foot-and-mouth disease virus elicited partial protection in mice

Author:
Yibao Chen; Yi Hu; Huanchun Chen; Xiangmin Li; Ping Qian
Source:
Vaccine 2020 v.38 no.35 pp. 5647-5652
ISSN:
0264-410X
Subject:
Foot-and-mouth disease virus; antibodies; antigens; ferritin; foot-and-mouth disease; immunogenicity; inactivated vaccines; interleukin-4; livestock; splenocytes; subunit vaccines; survival rate
Abstract:
... Foot-and-mouth disease (FMD) is an acute, febrile, and highly contagious infectious disease common in cloven-hoofed animals. Outbreaks and epidemics of FMD can result in major economic losses of livestock. Using ferritin nanoparticles as the scaffold for an antigen can enhance the immunogenicity of the subunit vaccine and provide possible protection against FMD. We used a baculovirus expression sy ...
DOI:
10.1016/j.vaccine.2020.06.063

35. A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G

Author:
Mark S. Riddle; Milton Maciel; Chad K. Porter; Steven T. Poole; Ramiro L. Gutierrez; Robert Gormley; Renee M. Laird; Peter J. Sebeny; Kathleen E. Dori; Melissa E. Greenleaf; Fahmida Hoq; George W. Turiansky; Abel Jarell; Douglas Hawk; David Tribble; Stephen J. Savarino
Source:
Vaccine 2020 v.38 no.45 pp. 7040-7048
ISSN:
0264-410X
Subject:
adhesins; antigens; blood serum; clinical trials; diarrhea; enterotoxigenic Escherichia coli; enterotoxins; fimbriae; humans; immunization; immunogenicity; mutation; pruritus; vaccines
Abstract:
... Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea among travelers and pediatric populations worldwide. The tip-localized adhesin of colonization factor antigen (CFA)/I fimbriae was engineered as a donor strand complemented variant (dscCfaE) and delivered via transcutaneous immunization. Preclinical vaccine testing demonstrated safety, immunogenicity and efficacy. A series of o ...
DOI:
10.1016/j.vaccine.2020.09.025

36. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants

Author:
Leyla Y. Bustamante; S. Josefin Bartholdson; Cecile Crosnier; Marta G. Campos; Madushi Wanaguru; Chea Nguon; Dominic P. Kwiatkowski; Gavin J. Wright; Julian C. Rayner
Source:
Vaccine 2013 v.31 no.2 pp. 373-379
ISSN:
0264-410X
Subject:
Plasmodium falciparum; antibodies; antigens; binding proteins; data collection; erythrocytes; evolution; genetic variation; humans; immune response; malaria; parasites; pathogenesis; sequence analysis; single nucleotide polymorphism; vaccine development; vaccines
Abstract:
... The lack of an effective licensed vaccine remains one of the most significant gaps in the portfolio of tools being developed to eliminate Plasmodium falciparum malaria. Vaccines targeting erythrocyte invasion – an essential step for both parasite development and malaria pathogenesis – have faced the particular challenge of genetic diversity. Immunity-driven balancing selection pressure on parasite ...
DOI:
10.1016/j.vaccine.2012.10.106
PubMed:
23146673
PubMed Central:
PMC3538003

37. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

Author:
Amalia Guadalupe Becerra Aquino; Maricruz Gutiérrez Brito; Carlos E. Aranza Doniz; Juan Francisco Galán Herrera; Mercedes Macias; Betzana Zambrano; Eric Plennevaux; Eduardo Santos-Lima
Source:
Vaccine 2012 v.30 no.45 pp. 6492-6500
ISSN:
0264-410X
Subject:
Enterovirus C; Mexicans; antigens; childhood; children; hemagglutinins; hepatitis B; immune response; infants; pertussis toxin; secondary immunization; tetanus; vaccination; vaccines; Mexico
Abstract:
... OBJECTIVES: To evaluate an investigational, fully liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae type b (DTaP-IPV-Hep B-PRP-T: Hexaxim™) vaccine for primary and booster vaccination of healthy children in Mexico. METHODS: Infants (N=1189) were randomized to receive one of three lots of the DTaP-IPV-Hep B-PRP-T vaccine or a licensed ...
DOI:
10.1016/j.vaccine.2012.07.040

38. A genotype VII Newcastle disease virus-like particles confer full protection with reduced virus load and decreased virus shedding

Author:
Xiaohong Xu; Zhuang Ding; Qianliang Yuan; Jiaxin Ding; Jindou Li; Weiqi Wang; Yanlong Cong; Wei Ouyang; Yongshan Wang; Jing Qian; Renfu Yin
Source:
Vaccine 2019 v.37 no.3 pp. 444-451
ISSN:
0264-410X
Subject:
Newcastle disease; proteins; antigens; flocks; vaccines; virus-like particles; Avian orthoavulavirus 1; genotype; virulent strains; viral load; vaccination; viral shedding; commercialization; birds; poultry industry
Abstract:
... Newcastle disease (ND) is one of the most severe avian infectious disease inflicting a great loss on poultry industry worldwide. The control of ND relies on proper vaccination strategies. The vaccine strains of Newcastle disease virus (NDV) mainly belong to genotype I, II or III, which cannot fully prohibit virus shedding against the prevalent genotype VII virulent strain attack. To develop a safe ...
DOI:
10.1016/j.vaccine.2018.11.068

39. A half-century of meningococcal vaccines

Author:
Andrew W. Artenstein
Source:
Vaccine 2021 v.39 no.17 pp. 2475-2478
ISSN:
0264-410X
Subject:
antibodies; antigens; encapsulation; immunity; polysaccharides; serotypes; vaccine development; vaccines
Abstract:
... The first safe and effective vaccine for the prevention of invasive meningococcal disease was created fifty years ago. The vaccine employed a novel platform, polysaccharide capsular antigen, based on the discovery that anticapsular antibody conferred protective immunity in humans. As with most new paradigms in vaccinology, it derived from important basic research from other scientific disciplines ...
DOI:
10.1016/j.vaccine.2021.03.024

40. A hemagglutinin-esterase-expressing salmonid alphavirus replicon protects Atlantic salmon (Salmo salar) against infectious salmon anemia (ISA)

Author:
Astrid Wolf; Kjartan Hodneland; Petter Frost; Stine Braaen; Espen Rimstad
Source:
Vaccine 2013 v.31 no.4 pp. 661-669
ISSN:
0264-410X
Subject:
Alphavirus; Infectious salmon anemia virus; Salmo salar; anemia; antigens; aquaculture; glycoproteins; immune response; industry; infectious salmon anemia; innate immunity; models; replicon; vaccination; vaccines
Abstract:
... A replicon expression system based on the salmonid alphavirus (SAV) that encodes the infectious salmon anemia virus (ISAV) hemagglutinin-esterase (HE) was constructed and found to be an efficacious vaccine against infectious salmon anemia (ISA). Following a single intramuscular immunization, Atlantic salmon (Salmo salar) were effectively protected against subsequent ISAV challenge. Additional repl ...
DOI:
10.1016/j.vaccine.2012.11.045

41. A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen

Author:
Sa Xiao; Manish Kumar; Xiuli Yang; Mustafa Akkoyunlu; Peter L. Collins; Siba K. Samal; Utpal Pal
Source:
Vaccine 2011 v.29 no.32 pp. 5294-5303
ISSN:
0264-410X
Subject:
chickens; hamsters; Lyme disease; blood serum; antigens; humans; hosts; vaccines; pathogens; mice; Avian orthoavulavirus 1; Borrelia burgdorferi; membrane proteins; viruses; immunization; surface proteins; Primates
Abstract:
... Newcastle disease virus (NDV) is an avian virus that is attenuated in primates and is a potential vaccine vector for human use. We evaluated NDV as a vector for expressing selected antigens of the Lyme disease pathogen Borrelia burgdorferi. A series of recombinant NDVs were generated that expressed intracellular or extracellular forms of two B. burgdorferi antigens: namely, the basic membrane prot ...
DOI:
10.1016/j.vaccine.2011.05.010
PubMed:
21600949
PubMed Central:
PMC3138909

42. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

Author:
David W. Porter; Fiona M. Thompson; Tamara K. Berthoud; Claire L. Hutchings; Laura Andrews; Sumi Biswas; Ian Poulton; Eric Prieur; Simon Correa; Rosalind Rowland; Trudie Lang; Jackie Williams; Sarah C. Gilbert; Robert E. Sinden; Stephen Todryk; Adrian V.S. Hill
Source:
Vaccine 2011 v.29 no.43 pp. 7514-7522
ISSN:
0264-410X
Subject:
Plasmodium falciparum; antigens; humans; immune response; interferon-gamma; malaria; parasitemia; safety assessment; subunit vaccines; transgenes; vaccination; volunteers
Abstract:
... We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria spor ...
DOI:
10.1016/j.vaccine.2011.03.083
PubMed:
21501642
PubMed Central:
PMC3195259

43. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model

Author:
Kelsey A. Gregg; Erin Harberts; Francesca M. Gardner; Mark R. Pelletier; Corinne Cayatte; Li Yu; Michael P. McCarthy; Jason D. Marshall; Robert K. Ernst
Source:
Vaccine 2018 v.36 no.28 pp. 4023-4031
ISSN:
0264-410X
Subject:
Toll-like receptor 4; Yersinia pestis; adjuvants; agonists; antibody formation; antigens; cell lines; cytokines; dendritic cells; humans; immunoglobulin G; ligands; mice; models; mononuclear leukocytes; pathogens; screening; structure-activity relationships; subunit vaccines; transcription factor NF-kappa B; vaccination
Abstract:
... Vaccination can significantly reduce worldwide morbidity and mortality to infectious diseases, thereby reducing the health burden as a result of microbial infections. Effective vaccines contain three components: a delivery system, an antigenic component of the pathogen, and an adjuvant. With the growing use of purely recombinant or synthetic antigens, there is a need to develop novel adjuvants tha ...
DOI:
10.1016/j.vaccine.2018.05.101
PubMed:
29861179
PubMed Central:
PMC6057149

44. A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice

Author:
Ellen K. Wasan; Jaweria Syeda; Stacy Strom; Jacqueline Cawthray; Robert E. Hancock; Kishor M. Wasan; Volker Gerdts
Source:
Vaccine 2019 v.37 no.11 pp. 1503-1515
ISSN:
0264-410X
Subject:
antigens; bioadhesives; blood serum; cholesterol; dose response; eggs; enzyme-linked immunosorbent assay; extrusion; fluorescence; gel electrophoresis; immune response; immunoglobulin A; immunoglobulin G; interferon-gamma; interleukin-5; intranasal administration; light scattering; macrophages; mice; mixing; mucins; mucosal immunity; nose; ovalbumin; phosphatidylethanolamines; physical properties; splenocytes; toxicity; transmission electron microscopy; vaccine adjuvants; vaccines; zeta potential
Abstract:
... We previously developed an highly efficacious combination adjuvant comprised of innate defense regulator (IDR)-1002 peptide, poly(I:C) and polyphosphazene (TriAdj). Here we aimed to design and test the in vivo efficacy of a mucoadhesive nasal formulation of this adjuvant. To determine the physical properties of the formulation, the effect of addition of each individual component was characterised ...
DOI:
10.1016/j.vaccine.2019.01.058

45. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes

Author:
Christopher C. Phelps; Stephen Vadia; Prosper N. Boyaka; Sanjay Varikuti; Zayed Attia; Purnima Dubey; Abhay R. Satoskar; Rodney Tweten; Stephanie Seveau
Source:
Vaccine 2020 v.38 no.36 pp. 5803-5813
ISSN:
0264-410X
Subject:
Listeria monocytogenes; T-lymphocytes; adjuvants; alum; amino acid sequences; antigens; cholera toxin; cholesterol; epithelium; immunization; listeriosis; liver; macrophages; microbial load; models; pathogenesis; pathogens; spleen; subunit vaccines; virulence
Abstract:
... Listeria monocytogenes is a facultative intracellular pathogen responsible for the life-threatening disease listeriosis. The pore-forming toxin listeriolysin O (LLO) is a critical virulence factor that plays a major role in the L. monocytogenes intracellular lifecycle and is indispensable for pathogenesis. LLO is also a dominant antigen for T cells involved in sterilizing immunity and it was propo ...
DOI:
10.1016/j.vaccine.2020.06.049

46. A live attenuated Vibrio anguillarum vaccine induces efficient immunoprotection in Tiger puffer (Takifugu rubripes)

Author:
Xiaohong Liu; Chenglong Jiao; Yue Ma; Qiyao Wang; Yuanxing Zhang
Source:
Vaccine 2018 v.36 no.11 pp. 1460-1466
ISSN:
0264-410X
Subject:
T-lymphocytes; Takifugu rubripes; Vibrio anguillarum; adults; antigens; aquaculture; aquaculture industry; body weight; breeding; cell-mediated immunity; fish; interferon-gamma; interleukin-10; interleukin-12; interleukin-15; interleukin-18; interleukin-1beta; interleukin-2; interleukin-6; interleukin-7; juveniles; live vaccines; major histocompatibility complex; pathogens; plasmids; tumor necrosis factor-alpha; vaccination; vibriosis; virulence; virulent strains; China
Abstract:
... Tiger puffer (Takifugu rubripes) is becoming an economic promising aquaculture species in China. However, the development of Tiger puffer breeding industry is restricted by some serious aquatic disease such as vibriosis. An effective live attenuated vaccine MVAV6203 was developed in our previous studies by curing the virulence plasmid pEIB1 and unmarked inframe-deletion of the aroC gene from the v ...
DOI:
10.1016/j.vaccine.2018.01.067

47. A live attenuated combination vaccine evokes effective immune-mediated protection against Edwardsiella tarda and Vibrio anguillarum

Author:
Yuan Gao; Haizhen Wu; Qiyao Wang; Jiangbo Qu; Qin Liu; Jingfan Xiao; Yuanxing Zhang
Source:
Vaccine 2014 v.32 no.45 pp. 5937-5944
ISSN:
0264-410X
Subject:
Danio rerio; Edwardsiella tarda; Toll-like receptors; Vibrio anguillarum; antibodies; antigens; aquaculture; bacteria; enzyme-linked immunosorbent assay; gene expression; gene expression regulation; kidneys; live vaccines; liver; signal transduction; spleen; turbot; vaccination; vibriosis; virulence
Abstract:
... Edwardsiella tarda and Vibrio anguillarum are the two main pathogenic bacteria that cause edwardsiellosis and vibriosis in various species of fish raised in aquaculture. In our previous study, the live attenuated vaccines E. tarda WED and V. anguillarum MVAV6203 showed robust relative protection when vaccinated zebrafish or turbot were challenged with virulent E. tarda or V. anguillarum, respectiv ...
DOI:
10.1016/j.vaccine.2014.08.074

48. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine

Author:
Rolando Pajon; Eduardo Lujan; Dan M. Granoff
Source:
Vaccine 2016 v.34 no.5 pp. 643-649
ISSN:
0264-410X
Subject:
antibacterial properties; antibodies; antigens; binding proteins; blood serum; disease outbreaks; endotoxins; gene overexpression; humans; mice; mutants; polysaccharides; serotypes; transgenic animals; vaccines; Nigeria
Abstract:
... Meningococcal epidemics in Sub-Sahara caused by serogroup A strains are controlled by a group A polysaccharide conjugate vaccine. Strains with serogroups C, W and X continue to cause epidemics. Protein antigens in licensed serogroup B vaccines are shared among serogroup B and non-B strains.Compare serum bactericidal antibody responses elicited by an investigational native outer membrane vesicle va ...
DOI:
10.1016/j.vaccine.2015.12.034
PubMed:
26709637
PubMed Central:
PMC4733268

49. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines

Author:
Anton P.J. Middelberg; Tania Rivera-Hernandez; Nani Wibowo; Linda H.L. Lua; Yuanyuan Fan; Graham Magor; Cindy Chang; Yap P. Chuan; Michael F. Good; Michael R. Batzloff
Source:
Vaccine 2011 v.29 no.41 pp. 7154-7162
ISSN:
0264-410X
Subject:
intranasal administration; freeze drying; antigens; antibodies; Mus musculus polyomavirus 1; bioreactors; geographical variation; manufacturing; chimerism; pathogens; mice; subcutaneous injection; vaccines; virus-like particles; immunization; Streptococcus; influenza; developed countries; Escherichia coli
Abstract:
... Studies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation ...
DOI:
10.1016/j.vaccine.2011.05.075

50. A mucosal adjuvant for the inactivated poliovirus vaccine

Author:
Benjamin P. Steil; Patricia Jorquera; Janny Westdijk; Wilfried A.M. Bakker; Robert E. Johnston; Mario Barro
Source:
Vaccine 2014 v.32 no.5 pp. 558-563
ISSN:
0264-410X
Subject:
Enterovirus C; adjuvants; antigens; blood serum; immunoglobulin A; immunoglobulin G; mice; mucosal immunity; neutralizing antibodies; rats; risk; serotypes; vaccines; viruses
Abstract:
... The eradication of poliovirus from the majority of the world has been achieved through the use of two vaccines: the inactivated poliovirus vaccine (IPV) and the live-attenuated oral poliovirus vaccine (OPV). Both vaccines are effective at preventing paralytic poliomyelitis, however, they also have significant differences. Most importantly for this work is the risk of revertant virus from OPV, the ...
DOI:
10.1016/j.vaccine.2013.11.101
PubMed:
24333345
PubMed Central:
PMC3967568